{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Immunodeficiency+Virus+Type+1+%28HIV-1%29&page=22", "query": { "condition": "Human Immunodeficiency Virus Type 1 (HIV-1)", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 1082, "total_pages": 109, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Immunodeficiency+Virus+Type+1+%28HIV-1%29&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Immunodeficiency+Virus+Type+1+%28HIV-1%29&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T09:35:25.908Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00006208", "title": "A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Efavirenz", "type": "DRUG" }, { "name": "Emtricitabine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Triangle Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-16T09:35:25.908Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Berkeley, California • Concord, California + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Berkeley", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006208" }, { "nct_id": "NCT02269917", "title": "Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Human Immunodeficiency Virus Type 1" ], "interventions": [ { "name": "D/C/F/TAF", "type": "DRUG" }, { "name": "Boosted Protease Inhibitor (bPI)", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1149, "start_date": "2015-03", "completion_date": "2020-10", "has_results": true, "last_update_posted_date": "2021-12-09", "last_synced_at": "2026-10-16T09:35:25.908Z", "location_count": 38, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269917" }, { "nct_id": "NCT00529243", "title": "Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "raltegravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kaiser Permanente", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2007-09", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2018-08-07", "last_synced_at": "2026-10-16T09:35:25.908Z", "location_count": 8, "location_summary": "Anaheim, California • Hayward, California • Los Angeles, California + 4 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Panorama City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00529243" }, { "nct_id": "NCT01810315", "title": "Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Prevention" ], "interventions": [ { "name": "TFV 1% gel", "type": "DRUG" }, { "name": "Estradiol vaginal cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CONRAD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "89 Years", "sex": "FEMALE", "summary": "21 Years to 89 Years · Female only" }, "enrollment_count": 40, "start_date": "2013-09", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2015-04-10", "last_synced_at": "2026-10-16T09:35:25.908Z", "location_count": 1, "location_summary": "Norfolk, Virginia", "locations": [ { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01810315" }, { "nct_id": "NCT01797445", "title": "Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "E/C/F/TDF", "type": "DRUG" }, { "name": "E/C/F/TDF Placebo", "type": "DRUG" }, { "name": "E/C/F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 872, "start_date": "2013-03-12", "completion_date": "2018-10-03", "has_results": true, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-10-16T09:35:25.908Z", "location_count": 79, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01797445" }, { "nct_id": "NCT03234400", "title": "A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Dapivirine Vaginal Ring, 25 mg", "type": "COMBINATION_PRODUCT" }, { "name": "Dapivirine Vaginal Ring, 100 mg", "type": "COMBINATION_PRODUCT" }, { "name": "Dapivirine Vaginal Ring, 200 mg", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "International Partnership for Microbicides, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 49, "start_date": "2017-12-04", "completion_date": "2019-01-23", "has_results": false, "last_update_posted_date": "2019-01-29", "last_synced_at": "2026-10-16T09:35:25.908Z", "location_count": 2, "location_summary": "Birmingham, Alabama • San Francisco, California", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03234400" }, { "nct_id": "NCT02616029", "title": "Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2015-12-17", "completion_date": "2019-07-11", "has_results": true, "last_update_posted_date": "2020-07-23", "last_synced_at": "2026-10-16T09:35:25.908Z", "location_count": 3, "location_summary": "Ft. Pierce, Florida • Orlando, Florida • West Palm Beach, Florida", "locations": [ { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02616029" }, { "nct_id": "NCT00262522", "title": "Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Human Immunodeficiency Virus Infections" ], "interventions": [ { "name": "lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 664, "start_date": "2005-11", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2012-02-06", "last_synced_at": "2026-10-16T09:35:25.908Z", "location_count": 30, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Fountain Valley, California + 23 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00262522" }, { "nct_id": "NCT00001031", "title": "A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "rgp120/HIV-1MN", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1 SF-2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "16 Years to 60 Years" }, "enrollment_count": 296, "start_date": null, "completion_date": "1997-12", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-16T09:35:25.908Z", "location_count": 7, "location_summary": "Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001031" }, { "nct_id": "NCT03499795", "title": "VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anal Neoplasm" ], "interventions": [ { "name": "VGX-3100", "type": "BIOLOGICAL" }, { "name": "CELLECTRA™ 5PSP", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2018-05-15", "completion_date": "2021-05-26", "has_results": true, "last_update_posted_date": "2023-07-14", "last_synced_at": "2026-10-16T09:35:25.908Z", "location_count": 2, "location_summary": "Chicago, Illinois • New York, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03499795" } ] }